中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
5-氯-3-甲基-4-硝基-1-苯基-1H-吡唑 | 5-chloro-3-methyl-4-nitro-1-phenyl-1H-pyrazole | 13551-76-3 | C10H8ClN3O2 | 237.645 |
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
3-甲基-1-苯基-1H-吡唑-4,5-二胺 | 4,5-diamino-3-methyl-1-phenylpyrazole | 52943-88-1 | C10H12N4 | 188.232 |
—— | 3'-methyl-4'-nitro-1'-phenyl-1,5'-bipyrazole | 86538-57-0 | C13H11N5O2 | 269.263 |
—— | 3'-methyl-4'-nitro-1'-p-nitrophenyl-1,5'-bipyrazole | 86549-36-2 | C13H10N6O4 | 314.26 |
—— | 4-bromo-3'-methyl-4'-nitro-1'-phenyl-1,5'-bipyrazole | 86538-65-0 | C13H10BrN5O2 | 348.159 |
—— | 4-chloro-3'-methyl-4'-nitro-1'-phenyl-1,5'-bipyrazole | 86538-67-2 | C13H10ClN5O2 | 303.708 |
—— | 4,4'-dinitro-3'-methyl-1'-phenyl-1,5'-bipyrazole | 86538-61-6 | C13H10N6O4 | 314.26 |
—— | 4,4'-dinitro-3'-methyl-1'-p-nitrophenyl-1,5'-bipyrazole | 86549-35-1 | C13H9N7O6 | 359.258 |
A series of synthetic N-phenylpyrazole arylhydrazone compounds, rationally designed as mixed-hybrid isosteres of two known inhibitors of prostaglandin synthase and 5-lipoxygenase enzymes, BW-755c and CBS-1108, has been investigated for anti-inflammatory activity in the carrageenan-induced pleurisy model in rats. The compounds have different oxygenated substituent groups in the aryl group of the hydrazone framework to ensure a different range of redox properties. A new arylhydrazone derivative, 2,6-di-tert-butyl-4-(4-nitro-3-methyl-N-phenylpyrazol-5-yl-hydrazonomethyl)phenol, was also synthesized and tested for anti-inflammatory activity.
Although all the compounds significantly inhibited (by 30–90%) neutrophil accumulation in the pleural cavity, there was great variability in the anti-oedematogenic effect of the compounds (3–96%). 5-(4′-Hydroxy-3′-methoxybenzylidene)hydrazone-3-methyl-4-nitrophenylpyrazole was the most active compound in this series; it had a remarkable antiinflammatory profile, almost blocking both assays. In contrast, the compound with a 2,6-di-tert-butylated hydroxybenzene ring on the hydrazone group inhibited neutrophil migration only.
These results will be useful for further structure-activity relationship studies devoted to improving the dual prostaglandin synthase-5-lipoxygenase activity of these derivatives and determining the minimum structural requirements necessary for this activity.
本研究对一系列合成的N-苯基吡唑芳基腙化合物进行了研究,这些化合物是合理设计的两种前列腺素合成酶和5-脂氧合酶酶抑制剂BW-755c和CBS-1108的混合杂合异构体。在大鼠海藻酸诱导的胸膜炎模型中研究了这些化合物的抗炎活性。这些化合物在腙基框架的芳基基团中具有不同的含氧取代基,以确保具有不同的氧化还原性质。还合成了一种新的芳基腙衍生物2,6-二叔丁基-4-(4-硝基-3-甲基-N-苯基吡唑-5-基腙甲基)酚,并测试了其抗炎活性。
虽然所有化合物均显著抑制(30-90%)胸腔内中性粒细胞的积聚,但这些化合物的抗水肿效果差异较大(3-96%)。5-(4'-羟基-3'-甲氧基苯甲亚)腙-3-甲基-4-硝基苯基吡唑是该系列中最活跃的化合物,具有显著的抗炎特性,几乎阻断了两种检测。相比之下,腙基团上带有2,6-二叔丁基羟基苯环的化合物仅抑制中性粒细胞迁移。
这些结果将有助于进一步的结构-活性关系研究,旨在改善这些衍生物的双重前列腺素合成酶-5-脂氧合酶活性,并确定此活性所需的最小结构要求。